Navigation Links
New Data Shows Ranexa(R) Increases Glucose-Stimulated Insulin Secretion
Date:3/31/2008

CHICAGO, March 31 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that preclinical research presented at the American College of Cardiology 57th Annual Scientific Session in Chicago showed that ranolazine increased glucose-stimulated insulin secretion (GSIS) in pancreatic islets isolated from animals and humans.

The Company believes that the increase in GSIS seen with ranolazine may contribute to the statistically significant reductions in hemoglobin A1c (HbA1c) levels observed with Ranexa in cardiovascular patients with diabetes from the phase 3 CARISA (n=189 with angina and diabetes) and MERLIN-TIMI 36 (n=2,220 with acute coronary syndromes and diabetes) clinical trials. In CARISA, Ranexa reduced HbA1c levels by an average of up to 0.7 percentage points. In MERLIN-TIMI 36, Ranexa lowered HbA1c versus placebo by an average of 0.43 percentage points at four months in patients with a mean baseline HbA1c level of 7.5%.

The preclinical results presented today showed that ranolazine increased GSIS in a dose-dependent manner in isolated islets. Acute administration of ranolazine to animals also significantly increased GSIS in the presence of a glucose load (p<0.05). Peak increases in insulin levels from ranolazine were similar to those seen with glibenclamide, a sulfonylurea used as a positive control. Unlike glibenclamide, in the absence of glucose ranolazine did not have any effect on insulin secretion.

"These data provide important additional information on the potential underlying mechanism which may be responsible for significant HbA1c reductions without associated hypoglycemia in both the CARISA and MERLIN-TIMI 36 studies," said Luiz Belardinelli, M.D., senior vice president of pharmaco
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
2. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
3. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
6. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
7. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
8. Feeling Anxious or Distracted? New Research Shows a Cup of Tea Could Help
9. New Study Shows Once-Monthly Boniva(R) is as Clinically Effective as Once-Weekly Fosamax(R) at Increasing Bone Mineral Density in Postmenopausal Women With Osteoporosis
10. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
11. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... DALLAS , Aug. 27, 2014 /PRNewswire-iReach/ -- "Fatty ... data on the Fatty Liver Disease clinical trial scenario. ... the clinical trials on Fatty Liver Disease . ... their recruitment status as per the site of trial ... coverage of disease clinical trials by their phase, trial ...
(Date:8/27/2014)... -- Ambit Biosciences (Nasdaq: AMBI ), a biopharmaceutical company ... in oncology, autoimmune and inflammatory disease, today announced the Company,s ... held at The New York Palace Hotel in ... Alan Fuhrman , Ambit,s CFO, will provide an ... at 1:10 p.m. ET on Wednesday, September 3, 2014.  The ...
(Date:8/27/2014)... REDWOOD CITY, Calif. , Aug. 27, 2014 ... in emergency response system design, blended emergency medical ... for CPR/AED (automated external defibrillator) training from the ... and the Army Reserve 81 st ... Homeland Security and Investigations contract includes nationwide CPR/AED/First ...
Breaking Medicine Technology:Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org 2Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org 3Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org 4Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org 5Ambit Announces Participation At Baird 2014 Health Care Conference 2Emergency University Equips Homeland Security, Army Reserve with SCA Response Program to Save Lives of Sudden Cardiac Arrest Victims 2Emergency University Equips Homeland Security, Army Reserve with SCA Response Program to Save Lives of Sudden Cardiac Arrest Victims 3
... March 1, 2011 Heska Corporation (Nasdaq: ... and specialty products to veterinarians, today announced the addition ... in-clinic blood analyzers. (Logo:   http://photos.prnewswire.com/prnh/20000622/HESKALOGO ) ... analyzer is used to measure lactate, and is ideal ...
... successful contract packaging and re-packaging companies in the ... new, single-source industry leader called Aphena Pharma ... corporation based on a strategic alliance between Celeste ... Packaging; all long-term specialized leaders in the contract ...
Cached Medicine Technology:Heska Introduces New Lactate Meter Analyzer 2Merger of Four Pharmaceutical Companies Announced 2
(Date:8/27/2014)... Overcoming a turbulent past which branded KC Armstrong ... Women’s Radio Network, WRNW1, has recently signed a multi-million dollar ... to the WRNW1 family. KC states, “it is such a ... atmosphere.” After KC Armstrong publicly announced his appreciation to Howard ... show, “Howard 100 News,” have decided to pay it forward. ...
(Date:8/27/2014)... IntelliSoft Group, LLC, a leading provider of ... IntelliCred, IntelliApp and IntelliContract Version 14.2 ... (NHAMSS) Annual Conference on September 16, 2014 at the ... Notable improvements available in IntelliSoft’s Version 14.2 ... Linking: A new Contract Connection Tab connects the healthcare ...
(Date:8/27/2014)... Time to Play Golf, a fast-growing golf ... , With 80-degree temperatures and only partially clouded skies, the ... Inaugural Outing. Around 50 golfers showed up to duel it ... Heron Glen Golf Course in Ringoes, New Jersey. , The ... be having a great time. Birdies were dropping and those ...
(Date:8/27/2014)... Los Angeles, California (PRWEB) August 27, 2014 ... unveiled its “Journey Candle Collection” to provide a growing number ... executives a scent-based tool for goal setting and relaxing at ... of six soy candles, uses scent memory and visualization to ... milestone in their life each time they light a candle ...
(Date:8/27/2014)... 2014 Michael A. Bottar ... of The Best Lawyers In America© for the practice ... Injury Litigation - Plaintiffs." , Bottar received his undergraduate ... laude graduate of Syracuse University College of Law where ... Practice" chapter of the Syracuse Law Review Survey of ...
Breaking Medicine News(10 mins):Health News:The Women's Radio Network, WRNW1, Signs KC Armstrong to a Multi-Million Dollar Contract 2Health News:IntelliSoft Group to Unveil Version 14.2 of IntelliCred, IntelliApp and IntelliContract at the New Hampshire Association of Medical Staff Services Annual Conference 2Health News:Recap: Time To Play Golf Inaugural Golf Outing 2Health News:In My Solitude Unveils Eco Candle Line That May Improve Performance 2Health News:Michael A. Bottar Selected For Inclusion In The Best Lawyers In America© 2015 2
... 25 WellPoint, Inc. (NYSE:,WLP) announced today that ... Healthcare Conference on January 30, 2008. The presentation ... Time., All interested parties are invited to ... http://www.wellpoint.com and selecting the "Investor,Info" link. ...
... 25, 2008 Researchers from Mayo Clinic in ... stents (SEPSs) in the treatment of benign esophageal disease ... stent migration and few cases of long-term improvement. They ... patient populations and to guide future recommendations for the ...
... must pass more than lip service reform in wake ... The following is a,statement by Executive Director, Kurt Entsminger, ... are among the most restrictive,in the nation. To get ... by the symptoms of an illness like,schizophrenia to be ...
... Bill Novelli,made the following statement about next Monday,s vote on ... by the California State Senate,Committee on Health:, "On behalf ... the members of the State Senate Health Committee to pass ... Monday. ABX 1 1 represents a major step toward,ensuring that ...
... Inc. ("Assurant"),(NYSE: AIZ ), a premier provider of ... its board of,directors has declared a quarterly dividend of ... March 10, 2008 to shareholders of record as of,Feb. ... at the discretion of the,board of directors and will ...
... 25, 2008 --New York, NY-- Researchers in Belgium have ... with the capacity to generate new insulin-producing beta cells. ... the newfound progenitor cells may represent an obvious target ... researchers report in the Jan. 25 issue of the ...
Cached Medicine News:Health News:WellPoint Announces Appearance at Upcoming Conference 2Health News:Study examines self-expanding plastic stents in the treatment of benign esophageal conditions 2Health News:Study examines self-expanding plastic stents in the treatment of benign esophageal conditions 3Health News:Virginia Must Prize Mental Illness Treatment Over Psychosis 2Health News:Virginia Must Prize Mental Illness Treatment Over Psychosis 3Health News:Elusive pancreatic progenitor cells found in mice 2
... The Bio-Optics LSM-12000 is a new ... powerful new tool in anterior segment diagnostics ... easy to operate, easy to maintain, and ... is the only High Magnification Slit-Lamp Biomicroscope ...
70 discs to investigate acquired color deficiency. Quantifies neutral zone characteristics of dyschromatopsia and evaluates the relative luminance....
... a rapid field or laboratory test for the ... simple, two-step test provides results in 10 minutes, ... , ,Intended use: The NOW® Hepatitis B sAg/eAg ... the detection of Hepatitis B surface antigen (HBsAg) ...
... the newest technology available in acrylic lens ... exceptional material and design properties to achieve ... , Unique foldable hydrophobic acrylic material ... biostable , High index of refraction ...
Medicine Products: